Jeff Landau is an accomplished corporate and business development executive with extensive experience in the biotech and pharmaceutical industry. He has over 20 years of experience in corporate development, new product planning, marketing, and sales. With an MBA in Health Care Entrepreneurship and Leadership from Stanford University Graduate School of Business and a BS in Biotechnology/Biochemistry from Virginia Tech, Jeff has developed an expertise in small and large molecules, AAV gene therapy, gene editing, companion diagnostics, and artificial intelligence. Jeff's professional experience includes his current position as Senior Vice President of Business Development, Corporate and Commercial Strategy at Catalyst Biosciences, where he has signed 15+ transactions including 20+ assets in orphan/rare disease, solid and liquid tumor oncology, benign hematology, hemophilia, ocular disorders, pulmonary (IPF/PAH), neurology/psychiatry, women’s health, and sleep medicine. Jeff has previously held positions including Healthcare Technology/Opportunity Reviewer at Band of Angels, Sr. Director of Corporate Development and Global Strategic Marketing at Threshold Pharmaceuticals, and Associate Director of Global Product Strategy and New Product Planning at Onyx Pharmaceuticals, Inc., an Amgen subsidiary. His resume also includes valuable pharma and biotech experience with roles such as MBA intern at Genentech, Senior Neuroscience Sales Specialist (Prozac, Zyprexa, Strattera, Cymbalta) at Eli Lilly and Company, and Senior Specialty Sales (Xyrem) at Jazz Pharmaceuticals and Orphan Medical. With Jeff's extensive experience in corporate and product development and his expertise in biotech and pharmaceuticals, he is an asset to any organization.